

AAAAI Foundation and Louis M. Mendelson, MD, FAAAAI Lectureship: Investing Together in Our Future



Louis M. Mendelson, MD, was born in Virginia and graduated from Vanderbilt University and Medical College of Virginia. He completed his Pediatric Residency at Bronx Municipal Hospital Center at the Albert Einstein School of Medicine in New York. Mendelson went on to complete his fellowship in Allergy and Immunology at the University of California in San Diego. Currently he is a Clinical Professor of Pediatrics at the University of Connecticut's School of Medicine and served as the Division Head of Allergy and Immunology at the Connecticut Children's Medical Center for many years; enthusiastically teaching and inspiring generations of medical students and pediatric residents.

Since 1972, Mendelson has been active in clinical private practices in the Hartford, Connecticut region, becoming a world renowned figure in our field because of his tireless dedication to his patients' care. His excellence as a clinician led to the American Academy of Allergy Asthma & Immunology (AAAAI) honoring him in 2000 with the Distinguished Clinician Award. He was previously honored with the Food Allergy Network's Marial C. Furlong Award for Making a Difference in 1999.

Despite his heavy practice schedule, he continues researching and writing, his interests include penicillin allergy, food allergy, anaphylactic reactions, asthma and vernal conjunctivitis; sharing his practical experiences improving our sub-specialty. He has been a champion of Regional Allergy Societies serving two terms as President of the Connecticut Allergy Society, and one term as President of the New England Society of Allergy. He served on the Board of Directors of the American Academy of Allergy, Asthma & Immunology (AAAAI), and was the Chairman of the AAAAI Foundation for two years and served on its Board for six years.

2019 marks the 3rd year of the AAAAI Foundation and Louis M. Mendelson, MD, FAAAAI Lectureship: Investing Together in Our Future lectureship. It will be presented in Plenary Session 3101: Systemic Regulation of Susceptibility and Pathogenesis of Allergic Inflammation on Sunday, February 24, 2019: 8:15 AM - 9:45 AM, Moscone Center South, Hall A

AAAAI Foundation and Louis M. Mendelson, MD, FAAAAI Lectureship Investing Together in Our Future – Dr. Cathryn Nagler, PhD



Cathryn R. Nagler is the Bunning Food Allergy Professor and Professor of Pathology, Medicine, Pediatrics and The College at the University of Chicago. She graduated with honors from Barnard College, Columbia University. Dr. Nagler obtained her Ph.D. from the Sackler Institute of Biomedical Science at N.Y.U. School of Medicine and did a postdoctoral fellowship at M.I.T. She was Associate Professor of Pediatrics (Immunology) at Harvard Medical School prior to joining the University of Chicago in 2009.

Dr. Nagler has participated in numerous review panels for the Crohn's and Colitis Foundation of America, NIDDK and NIAID, including the Food Allergy Expert Panel. She is in her second term on the research advisory board for Food Allergy Research and Education (FARE). She has served the American Association of Immunologists (AAI) as Section Editor for the *Journal of Immunology*, Instructor for the Introduction to Immunology and Advanced Immunology courses and as member of the Program, Clinical Immunology, Publications and Awards Committees.

She was an inaugural senior editor for the AAI's new journal *ImmunoHorizons*. She is currently Deputy Editor for the *Journal of Immunology*. She has also served as an elected Councilor of the Society for Mucosal Immunology and is an Associate Editor of the journal *Mucosal Immunology*. She recently began teaching in the FOCIS Advanced Course in Basic and Clinical Immunology and joined the FOCIS Education Committee. Dr. Nagler has a long-standing interest in the mechanisms governing tolerance to dietary antigens and the potential immunomodulatory features of the oral route of antigen administration. Her most recent work examines how commensal bacteria regulate susceptibility to allergic responses to food. She has applied insights gained from studying pre-clinical gnotobiotic murine models of cow's milk allergy to launch a new company, ClostraBio, which is developing microbiome-modulating therapeutics for the prevention and treatment of food allergy.